Med Ad News talked to Sharon Callahan, the new CEO of CDM, and Robin Shapiro, who moved into the position of CEO of TBWA\WorldHealth, about changes at their agencies and what it’s like taking on new roles at a time when COVID-19 has literally changed everything about the way that everyone works.
AbelsonTaylor – one of the world’s premier health and wellness advertising agencies – promoted Lynnette Hunter to executive vice president, director of client services, and Jeanine Koch to executive vice president, director of project management.
McCann Health announced Hilary Gentile’s promotion to the newly created position of Global Chief Strategy Officer.
CMI/Compas, media buying and planning for the nation’s top healthcare companies and part of WPP, announced the promotion of Gia Mauriello to EVP, Customer Experience and Excellence.
The Bloc, one of the largest independent health creative agencies, announced the promotion of Jennifer Matthews to CEO and president. Founding partners Susan Miller Viray and Rico Viray assume the respective positions of chairman of The Bloc and chairman of the global network The BlocPartners.
One is going, one is staying – and getting a promotion.
CMI/Compas announced the promotion of Dr. Susan Dorfman to President, CMI. Dorfman was previously Chief Commercial Officer for CMI/Compas.
WPP announced the appointment of Mark Read as Chief Executive Officer and his appointment to the Board of WPP as an Executive Director with immediate effect.
Ogilvy CommonHealth Worldwide announced the promotions of Raymond Johnson, Laura Kohler, and Beth Lebowitz all from VP, management supervisors, to SVP, management supervisors, within the organization’s NJ-based market access team.
Gilead Sciences Inc. announced that Gregg Alton was appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, was promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, decided to leave Gilead to pursue another opportunity.
